Xin Lang Cai Jing·2025-09-29 10:40Core Viewpoint - Genmab A/S has announced a cash acquisition of Merus NV for $97.00 per share, valuing the transaction at approximately $8 billion, which is expected to accelerate Genmab's transition to a fully integrated model and enhance its revenue sources [1][2]. Group 1: Transaction Details - The acquisition will be conducted in cash, with a total transaction value of about $8 billion [1]. - The deal has received unanimous approval from the boards of both companies [2]. - Genmab's wholly-owned subsidiary will initiate a tender offer for 100% of Merus's common stock, anticipated to be completed in early Q1 2026 [2]. Group 2: Financial Aspects - The acquisition price of $97.00 per share represents a premium of approximately 41% over Merus's closing price of $68.89 on September 26, 2025 [2]. - The offer also reflects a premium of about 44% compared to Merus's 30-day volume-weighted average price of $67.42 [2]. Group 3: Strategic Implications - Acquiring Merus is expected to significantly accelerate Genmab's transition to a fully integrated model [2]. - The acquisition aims to expand and enrich Genmab's revenue sources, driving sustained growth over the next decade [2]. - This move positions Genmab to become a leader in the biotechnology sector [2].